Osteotech has received 510(k) clearance for this material as a bone graft substitute, and as a bone void filler, for use in the spine, pelvis and extremities.
Sam Owusu-Akyaw, president and CEO of Osteotech, said: “Receiving FDA clearance for our next generation grafting material is a great accomplishment for our team and another key milestone in our strategic plan.”